Hemodynamic effects of treatment with the ketone body 3-hydroxybutyrate in cardiogenic shock - a randomized, controlled, assessor-blinded porcine trial
Oskar Kjærgaard Hørsdal(Aarhus University Hospital), Kristoffer Berg‐Hansen(Aarhus University), O K L Helgestad(Aarhus University Hospital), Roni Nielsen(Aarhus University), Kasper Lykke Wethelund(Aarhus University), Nigopan Gopalasingam(Aarhus University Hospital), Henrik Wiggers(Aarhus University)
Cited by 0
Related Papers
Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2018|716
Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
|European Journal of Heart Failure|2016|561
Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients
|Circulation|2019|526
Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study
|Journal of the American Heart Association|2017|235
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
|American Journal of Physiology-Heart and Circulatory Physiology|2010|165